Akero Therapeutics Inc (AKRO) |
|
26.24 0.43 (1.67%)
|
10-23 23:33 |
|
Open: |
26.04 |
Pre. Close: |
25.81 |
|
High:
|
26.4699 |
Low:
|
25.74 |
|
Volume:
|
115,116 |
Market Cap:
|
911M |
|
|
|
|
Akero Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 10 full-time employees. The firm is engaged in nonalcoholic steatohepatitis (NASH), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease, or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. The Company’s lead product candidate, AKR-001, which the Company is developing as a treatment for patients with NASH, is an analog of fibroblast growth factor 21 (FGF21). FGF21 is an endogenously-expressed hormone that regulates metabolism of lipids, carbohydrates and proteins throughout the body. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
26.515 - 26.642 |
26.642 - 26.757 |
|
Low:
|
25.427 - 25.575 |
25.575 - 25.709 |
|
Close:
|
25.996 - 26.239 |
26.239 - 26.46 |
|
Technical analysis |
as of: 2020-10-23 4:40:25 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 37.85  One year: 42.84 |
| Support: |
Support1: 25.50 Support2: 21.21 |
| Resistance: |
Resistance1: 32.41 Resistance2: 36.68 |
| Pivot: |
27.99 |
| Moving Average: |
MA(5): 26.38 MA(20): 28.59
MA(100): 31.89 MA(250): 25.64 |
| MACD: |
MACD(12,26): -1.70 Signal(9): -1.53 |
| Stochastic oscillator: |
%K(14,3): 7.82 %D(3): 8.32 |
| RSI: |
RSI(14): 31.66 |
| 52-week: |
High: 41.16 Low: 10.78 Change(%): 29.8 |
| Average Vol(K): |
3-Month: 18573 10-Days: 20694 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.AKRO has closed above bottom band by 15.8%. Bollinger Bands are 26.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 21 Oct 2020
Akero Therapeutics To Present At Upcoming Conferences In November - Yahoo Finance
Fri, 16 Oct 2020
Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH - PRNewswire
Wed, 07 Oct 2020
Is Akero Therapeutics Inc (AKRO) Stock a Great Value? - InvestorsObserver
Wed, 30 Sep 2020
H.C. Wainwright Stick to Their Buy Rating for Akero Therapeutics Inc - Investing.com
Wed, 30 Sep 2020
Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients In Ongoing Balanced Study - PRNewswire
Tue, 29 Sep 2020
Chart Analysis: Get Key Insights on Akero Therapeutics, Inc. (AKRO) - Invest Million
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
35 |
| Shares Float (M) |
18 |
|
% Held by Insiders
|
9.51 |
|
% Held by Institutions
|
84.23 |
|
Shares Short (K)
|
984 |
|
Shares Short P. Month (K)
|
778 |
Stock Financials |
|
EPS
|
-2.080 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
3.610 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-27.7 |
|
Return on Equity (ttm)
|
-45.2 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
|
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-59 |
|
Levered Free Cash Flow (M)
|
-39 |
Stock Valuations |
|
PE Ratio
|
-12.62 |
|
PEG Ratio
|
|
|
Price to Book value
|
7.27 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-15.50 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
